BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Clinical trial NCT07151690 · RECRUITING

Trial details

NCT number: NCT07151690
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Systemic Light Chain Amyloidosis

Start date: 2025-09-04
Primary completion: 2026-12-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.